Literature DB >> 23890143

Contrasts and comparisons between childhood and adult onset acute pancreatitis.

Anell Meyer1, Michael J Coffey, Mark R Oliver, Chee Y Ooi.   

Abstract

Acute pancreatitis (AP) in children is an increasingly recognised clinical entity notably different from the adults with respect to incidence, aetiology, severity and outcome. Yet our current understanding and approach to the management of paediatric pancreatitis is based almost entirely on adult studies. Acute recurrent pancreatitis (ARP) in children is more likely associated with various genetic factors, some of which have been relatively well characterised and others are in an evolving phase. The aim of this review is to summarise current knowledge, highlight any recent advances and contrast the paediatric and adult forms of this condition.
Copyright © 2013 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute pancreatitis; Children; Genetic testing; Paediatric; Recurrent pancreatitis

Mesh:

Substances:

Year:  2013        PMID: 23890143     DOI: 10.1016/j.pan.2013.06.005

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  3 in total

1.  Prevalence of Pancreatitis in Female and Male Pediatric Patients in Eastern Kentucky in the United States.

Authors:  Sabrina L McIlwrath; Karin N Westlund
Journal:  J Fam Med Community Health       Date:  2016-11-12

2.  Use of Lactated Ringers Solution Compared With Normal Saline Is Associated With Shorter Length of Stay in Pediatric Acute Pancreatitis.

Authors:  Peter R Farrell; Leslie M Farrell; Lindsey Hornung; Maisam Abu-El-Haija
Journal:  Pancreas       Date:  2020-03       Impact factor: 3.243

Review 3.  Corticosteroid treatment for acute/acute-on-chronic experimental and naturally occurring pancreatitis in several species: a scoping review to inform possible use in dogs.

Authors:  Kari-Anne Bjørnkjær-Nielsen; Charlotte Reinhard Bjørnvad
Journal:  Acta Vet Scand       Date:  2021-07-13       Impact factor: 1.695

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.